Table 4. Associations of four factor scores with each Fatty Liver Index component.
Q1 | Q2 | Q3 | Q4 | P for trend | |
OR | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||
Body mass index ≥25 kg/m2 | |||||
Factor 1 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 127 (32.0) | 108 (27.2) | 92 (23.2) | 62 (15.6) | |
Model 2a | 1.00 | 0.92 (0.66–1.26) | 0.72 (0.52–1.01) | 0.48 (0.33–0.71) | 0.0002 |
Factor 2 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 88 (22.2) | 105 (26.5) | 82 (20.7) | 114 (28.7) | |
Model 2 | 1.00 | 1.45 (1.03–2.04) | 1.10 (0.77–1.57) | 1.64 (1.17–2.32) | 0.03 |
Factor 3 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 118 (29.7) | 108 (27.2) | 83 (20.9) | 80 (20.2) | |
Model 2 | 1.00 | 0.98 (0.71–1.36) | 0.75 (0.53–1.05) | 0.77 (0.54–1.09) | 0.06 |
Factor 4 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 96 (24.2) | 99 (24.9) | 101 (25.4) | 93 (23.4) | |
Model 2 | 1.00 | 1.05 (0.75–1.47) | 1.09 (0.78–1.52) | 0.99 (0.70–1.39) | 0.97 |
| |||||
Triglycerides ≥150 mg/dL | |||||
Factor 1 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 84 (21.2) | 64 (16.1) | 69 (17.4) | 53 (13.4) | |
Model 2 | 1.00 | 0.83 (0.57–1.21) | 1.00 (0.68–1.47) | 0.89 (0.58–1.38) | 0.82 |
Factor 2 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 81 (20.4) | 67 (16.9) | 66 (16.6) | 56 (14.1) | |
Model 2 | 1.00 | 0.90 (0.61–1.31) | 1.00 (0.68–1.46) | 0.73 (0.49–1.09) | 0.20 |
Factor 3 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 84 (21.2) | 68 (17.1) | 61 (15.4) | 57 (14.4) | |
Model 2 | 1.00 | 0.90 (0.62–1.31) | 0.89 (0.60–1.30) | 0.95 (0.64–1.41) | 0.74 |
Factor 4 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 62 (15.6) | 72 (18.1) | 70 (17.6) | 66 (16.6) | |
Model 2 | 1.00 | 1.26 (0.86–1.86) | 1.19 (0.81–1.77) | 1.13 (0.76–1.68) | 0.63 |
| |||||
Waist circumference (male ≥90 cm, female ≥80 cm) | |||||
Factor 1 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 120 (30.2) | 111 (28.0) | 115 (29.0) | 110 (27.7) | |
Model 2 | 1.00 | 0.81 (0.59–1.12) | 0.79 (0.57–1.10) | 0.63 (0.44–0.90) | 0.02 |
Factor 2 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 104 (26.2) | 105 (26.5) | 115 (29.0) | 132 (33.3) | |
Model 2 | 1.00 | 1.06 (0.77–1.47) | 1.21 (0.88–1.68) | 1.61 (1.16–2.23) | 0.003 |
Factor 3 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 127 (32.0) | 110 (27.7) | 114 (28.7) | 105 (26.5) | |
Model 2 | 1.00 | 0.81 (0.59–1.12) | 0.85 (0.62–1.17) | 0.69 (0.50–0.96) | 0.04 |
Factor 4 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 99 (24.9) | 104 (26.2) | 131 (33.0) | 122 (30.7) | |
Model 2 | 1.00 | 1.09 (0.79–1.52) | 1.43 (1.04–1.96) | 1.28 (0.93–1.77) | 0.05 |
| |||||
γ-Glutamyl transpeptidase (male ≥85 IU/L, female ≥38 IU/L) | |||||
Factor 1 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 34 (8.6) | 37 (9.3) | 43 (10.8) | 37 (9.3) | |
Model 2 | 1.00 | 1.04 (0.63–1.72) | 1.16 (0.71–1.91) | 0.91 (0.53–1.58) | 0.85 |
Factor 2 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 32 (8.1) | 39 (9.8) | 46 (11.6) | 34 (8.6) | |
Model 2 | 1.00 | 1.34 (0.82–2.21) | 1.64 (1.01–2.68) | 1.20 (0.71–2.03) | 0.36 |
Factor 3 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 44 (11.1) | 38 (9.6) | 33 (8.3) | 36 (9.1) | |
Model 2 | 1.00 | 0.86 (0.54–1.37) | 0.70 (0.43–1.14) | 0.79 (0.48–1.28) | 0.24 |
Factor 4 | n = 397 | n = 397 | n = 397 | n = 397 | |
Number of cases (%) | 32 (8.1) | 32 (8.1) | 44 (11.1) | 43 (10.8) | |
Model 2 | 1.00 | 1.01 (0.60–1.68) | 1.38 (0.86–2.26) | 1.28 (0.78–2.09) | 0.19 |
CI, confidence interval; OR, odds ratio; Q, quartile.
aAdjusted for sex, age, research group, smoking, amount of ethanol intake, total energy intake, and physical activity level.